Ainnocence is a global biotech company that leads in generative AI for therapeutic discovery, leveraging industry grade sequence-based proprietary technology and training data from over 16 years expertise.
Problem: costly high throughput wet lab screening, expensive structure biology and inaccurate 3D modeling processes.
Solution: A radical AI drug discovery system that accelerates the discovery of life-saving therapies with unprecedented speed, large and deep virtual throughput and higher success rates, for all therapeutic targets.
By working directly from primary sequence data, it eliminates the need for external 3-D structure-prediction software and other open-source packages. Instead, our technology performs ultra-high-throughput virtual screening and multi-objective optimisation, evaluating up to 10¹⁰ candidates within hours to days—giving our partners capabilities that off-the-shelf tools cannot match.
